Kraig Biocraft Laboratories Successfully Completes Recombinant Cocoon Production From Spring Trials - Seite 2

The current production trial will continue to run for two or three weeks. Additional data on each of the four production batches is being collected and processed. "We are 85% to 90% through the trial of the parental strains, and every single batch of our new strains sailed through what we expected to be the toughest challenges," continued Thompson. "Even in advance of the conclusion of the trials, I am happy to report that our two-year program of acclimation to the production environment appears to have been achieved."

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news

Kraig Labs’ specialized recombinant spider silk silkworms spinning cocoons

Kraig Labs’ BAM-1 cocoons on mountage

BAM-1 spider silk cocoons under UV light

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.